658
Participants
Start Date
June 30, 2013
Primary Completion Date
May 22, 2015
Study Completion Date
January 15, 2021
Cabozantinib tablets
Everolimus (Afinitor) tablets
Dublin
Dublin
Helsinki
Brussels
Vienna
Vienna
Budapest
Darlinghurst
Antwerp
Randwick
Wahroonga
Concord
Westmead
Kogarah
Bonheiden
Brasschaat
Leuven
Box Hill
Bentleight East
Wodonga
Liège
Linz
Milton
Wooloongabba
Adelaide
Szolnok
Ankara
Hobart
Roeselare
New York
Berlin
Albany
Marseille
Caen
Pittsburgh
Santiago de Compostela
Genoa
Philadelphia
Washington D.C.
Hamburg
Baltimore
Baltimore
Durham
Besançon
Gaziantep
Madrid
Madrid
Seville
Madrid
Charleston
Hanover
Pamplona
Toulouse
Oviedo
Bordeaux
Miami
Miami
Gütersloh
Boca Raton
Tampa
Istanbul
Rennes
Izmir
Nashville
Nashville
Knoxville
Memphis
Modena
Columbus
Cleveland
Cleveland
Nantes
Essen
Valencia
Meldola
Ravenna
Ann Arbor
Detroit
Detroit
Aachen
Arezzo
Iowa City
Mainz
Rochester
Frankfurt am Main
Chicago
Chicago
Chicago
St Louis
Westwood
Heidelberg
Bari
Le Mans
Tübingen
Dallas
Paris
Bedford
Fort Worth
Houston
Houston
San Antonio
Austin
Freiburg im Breisgau
Aurora
Denver
Munich
München
Salt Lake City
Gilbert
Scottsdale
Tucson
Ulm
Las Vegas
Los Angeles
Los Angeles
Duarte
Erlangen
La Jolla
Vallejo
Villejuif
Lyon
Portland
Portland
Seattle
Vancouver
Yakima
Erfurt
Jena
Anchorage
Moscow
Yaroslavl
Saint Petersburg
Omsk
Birmingham
Port Macquarie
Santiago
Seoul
Stockholm
Umeå
Taichung
Taipei
London
Glasgow
New Haven
Orlando
Boston
La Plata
Mar del Plata
Calgary
Edmonton
Vancouver
Winnepeg
Halifax
Hamilton
Kingston
London
Oshawa
Ottawa
Toronto
Toronto
Montreal
Saskatoon
Olomouc
Brno
Prague
Herlev
Aarhus
Odense
Turku
Dresden
Rome
Rome
Cremona
Terni
Maastricht
Amsterdam
Leiden
Rotterdam
Poznan
Bialystok
Gdansk
Warsaw
Lisbon
Lisbon
Porto
Prešov
Žilina
Seoul
Seoul
Badalona
Barcelona
L'Hospitalet de Llobregat
Barcelona
Málaga
Lund
Birmingham
Derby
Guildford
London
London
Manchester
Metropolitan Borough of Wirral
Northwood
Aberdeen
Edinburgh
Lead Sponsor
Exelixis
INDUSTRY